GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data (Q60044940)

24 March 2019

17 June 2019

31 July 2019

17 November 2019

18 November 2019

15 December 2019

27 October 2020

26 January 2021

4 February 2021

on focus list of Wikimedia project

19 July 2022

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/s12933-018-0800-2

0 references

cites work

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

1 reference

12 December 2020

Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats

1 reference

12 December 2020

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

12 December 2020

Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Diabetes and decline in heart disease mortality in US adults.

1 reference

12 December 2020

Insulin resistance and cardiovascular disease

1 reference

12 December 2020

Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus

1 reference

12 December 2020

Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat.

1 reference

12 December 2020

The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion

1 reference

12 December 2020

Entry of exendin-4 into brain is rapid but may be limited at high doses

1 reference

12 December 2020

GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine

1 reference

12 December 2020

NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE

1 reference

12 December 2020

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION

1 reference

12 December 2020

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

12 December 2020

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

1 reference

12 December 2020

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

12 December 2020

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

1 reference

12 December 2020

The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism

1 reference

12 December 2020

Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects

1 reference

12 December 2020

Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts.

1 reference

12 December 2020

On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane

1 reference

12 December 2020

Cell-permeable, mitochondrial-targeted, peptide antioxidants

1 reference

12 December 2020

Exenatide: a novel approach for treatment of type 2 diabetes

1 reference

12 December 2020

Biology of incretins: GLP-1 and GIP

1 reference

12 December 2020

Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart

1 reference

12 December 2020

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

1 reference

12 December 2020

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

12 December 2020

Effects of intensive glucose lowering in type 2 diabetes

1 reference

12 December 2020

1 reference

12 December 2020

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

12 December 2020

Long-term follow-up after tight control of blood pressure in type 2 diabetes.

1 reference

12 December 2020

Diabetes and atherosclerosis: is there a role for hyperglycemia?

1 reference

12 December 2020

No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects

1 reference

12 December 2020

Efficient mitochondrial targeting relies on co-operation of multiple protein signals in plants

1 reference

12 December 2020

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

1 reference

12 December 2020

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

1 reference

12 December 2020

Incretin-based therapies: viewpoints on the way to consensus

1 reference

12 December 2020

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide

1 reference

12 December 2020

Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis

1 reference

12 December 2020

Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.

1 reference

12 December 2020

Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency

1 reference

12 December 2020

Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus

1 reference

12 December 2020

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

1 reference

12 December 2020

Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase

1 reference

12 December 2020

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

1 reference

12 December 2020

Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes.

1 reference

12 December 2020

The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study.

1 reference

12 December 2020

GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes.

1 reference

12 December 2020

A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.

1 reference

12 December 2020

Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care

1 reference

12 December 2020

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

1 reference

12 December 2020

Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels

1 reference

12 December 2020

Cellular dysfunction in diabetes as maladaptive response to mitochondrial oxidative stress

1 reference

12 December 2020

GLP1-derived nonapeptide GLP1(28-36)amide protects pancreatic β-cells from glucolipotoxicity

1 reference

12 December 2020

GLP-1 and cardioprotection: from bench to bedside

1 reference

12 December 2020

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

1 reference

12 December 2020

Postprandial dyslipidaemia and diabetes: mechanistic and therapeutic aspects

1 reference

12 December 2020

Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research

1 reference

12 December 2020

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

1 reference

12 December 2020

Liraglutide, a long-acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage

1 reference

12 December 2020

Postprandial dysmetabolism and the heart

1 reference

12 December 2020

The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial

1 reference

12 December 2020

Standards of medical care in diabetes--2013

1 reference

12 December 2020

Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study).

1 reference

12 December 2020

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials

1 reference

12 December 2020

Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients

1 reference

12 December 2020

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I

1 reference

12 December 2020

The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model.

1 reference

12 December 2020

Pharmacology, physiology, and mechanisms of incretin hormone action

1 reference

12 December 2020

Glucagon-like peptide-1 analogues: An overview

1 reference

12 December 2020

Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation.

1 reference

12 December 2020

Lixisenatide: a review of its use in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Endothelial dysfunction - a major mediator of diabetic vascular disease

1 reference

12 December 2020

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab

1 reference

12 December 2020

Neuroprotective effects of liraglutide for stroke model of rats

1 reference

12 December 2020

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

1 reference

12 December 2020

Regulation of glucose homeostasis by GLP-1

1 reference

12 December 2020

Incretin therapy and heart failure

1 reference

12 December 2020

Glucagon-like peptide-1 as a key regulator of lipid and lipoprotein metabolism in fasting and postprandial states

1 reference

12 December 2020

The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.

1 reference

12 December 2020

Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide

1 reference

12 December 2020

HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea

1 reference

12 December 2020

Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists

1 reference

12 December 2020

Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke

1 reference

12 December 2020

Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans

1 reference

12 December 2020

Liraglutide and obesity: a review of the data so far.

1 reference

12 December 2020

Flow-mediated dilation: An evolving method

1 reference

12 December 2020

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis

1 reference

12 December 2020

Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide

1 reference

12 December 2020

Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis

1 reference

12 December 2020

A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes

1 reference

12 December 2020

Mechanisms for the cardiovascular effects of glucagon-like peptide-1.

1 reference

12 December 2020

Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists

1 reference

12 December 2020

Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

1 reference

12 December 2020

Tanzeum (Albiglutide): A Once-Weekly GLP-1 Receptor Agonist Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes

1 reference

12 December 2020

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

1 reference

12 December 2020

Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis

1 reference

12 December 2020

Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events

1 reference

12 December 2020

Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis.

1 reference

12 December 2020

Emerging role of the brain in the homeostatic regulation of energy and glucose metabolism

1 reference

12 December 2020

Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction.

1 reference

12 December 2020

Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future

1 reference

12 December 2020

Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner

1 reference

12 December 2020

Glucagon-Like Peptide 1 Receptor Activation and Platelet Function: Beyond Glycemic Control

1 reference

12 December 2020

Molecular and Cellular Mechanisms of Cardiovascular Disorders in Diabetes

1 reference

12 December 2020

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

1 reference

12 December 2020

Dulaglutide (Trulicity): The Third Once-Weekly GLP-1 Agonist

1 reference

12 December 2020

Hypoglycemia and Cardiovascular Risk: Is There a Major Link?

1 reference

12 December 2020

Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study

1 reference

12 December 2020

Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial

1 reference

12 December 2020

Targeting the gastrointestinal tract to treat type 2 diabetes

1 reference

12 December 2020

The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia

1 reference

12 December 2020

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

1 reference

12 December 2020

Population pharmacokinetics of exenatide

1 reference

12 December 2020

Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.

1 reference

12 December 2020

Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes.

1 reference

12 December 2020

Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.

1 reference

12 December 2020

Effects of Liraglutide on Reperfusion Injury in Patients With ST-Segment-Elevation Myocardial Infarction

1 reference

12 December 2020

GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products.

1 reference

12 December 2020

Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies

1 reference

12 December 2020

Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species

1 reference

12 December 2020

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes

1 reference

12 December 2020

GLP-1 receptor agonists and heart failure in diabetes.

1 reference

12 December 2020

After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?

1 reference

12 December 2020

Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.

1 reference

12 December 2020

The safety of albiglutide for the treatment of type 2 diabetes

1 reference

12 December 2020

An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review

1 reference

12 December 2020

Thrombotic and cardiovascular risks in type two diabetes; Role of platelet hyperactivity.

1 reference

12 December 2020

Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes

1 reference

12 December 2020

Glucagon-like receptor 1 agonists and DPP-4 inhibitors: Anti-diabetic drugs with anti-stroke potential

1 reference

12 December 2020

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.

1 reference

12 December 2020

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

1 reference

12 December 2020

Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity.

1 reference

12 December 2020

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.

1 reference

12 December 2020

Lixisenatide (Adlyxin): A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes.

1 reference

12 December 2020

A New Treatment Strategy for Parkinson's Disease Through the Gut-Brain Axis: The Glucagon-like Peptide-1 Receptor Pathway

1 reference

12 December 2020

A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.

1 reference

12 December 2020

Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.

1 reference

12 December 2020

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.

1 reference

12 December 2020

Semaglutide-the "new kid on the block" in the field of glucagon-like peptide-1 receptor agonists?

1 reference

12 December 2020

The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors.

1 reference

12 December 2020

Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk.

1 reference

12 December 2020

Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis

1 reference

12 December 2020

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data.

1 reference

12 December 2020

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes.

1 reference

12 December 2020

Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.

1 reference

12 December 2020

The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World Data

1 reference

12 December 2020

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

1 reference

12 December 2020

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

1 reference

12 December 2020